Pediatric Intestine Transplant Recipient Registration Worksheet

Note: These worksheets are provided to function as a guide to what data will be required in the online $TIEDI^{(0)}$ application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online $TIEDI^{(0)}$ application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Recipient Information	
Name:	DOB:
SSN:	Birth sex:
HIC:	Transplant Date and Time:
State of Permanent Residence: *	Time.
Permanent Zip: *	
Provider Information	
Recipient Center:	
Surgeon Name: *	
NPI#:*	
Donor Information	
UNOS Donor ID #:	
Recovering OPO:	
Donor Type:	
Patient Status	
Primary Diagnosis: *	
Specify:	
Secondary Diagnosis:	\leftarrow
Specify:	
Date: Last Seen, Retransplanted or Death*	
Patient Status:*	OLIVING
	DEAD
	RETRANSPLANTED
Primary Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Transplant Hospitalization:	
Date of Admission to Tx Center: *	
Date of Discharge from Tx Center:	
Clinical Information : PRETRANSPLANT Medical Condition at time of transplant: *	OIN INTENSIVE CARE UNIT
reducal condition at time of transplants.	
	OHOSPITALIZED NOT IN ICU
	ONOT HOSPITALIZED
Patient on Life Support: *	OYES ONO
	☐ Ventilator
	Artificial Liver
Coorie	Other Mechanism, Specify
Specify:	
Functional Status: *	
	gan Sharing. All rights reserved. OPTN use only. 091423

Cognitive Development: *	Operative Cognitive	e delay/impairment
	Probable Cognitive	e delay/impairment
	Questionable Cogn	nitive delay/impairment
	No Cognitive dela	y/impairment
	Not Assessed	
Motor Development: *	Opefinite Motor del	lay/impairment
	Probable Motor de	elay/impairment
	Questionable Mote	or delay/impairment
	No Motor delay/in	npairment
	Not Assessed	
Academic Progress:*	OWithin One Grade	Level of Peers
	ODelayed Grade Lev	vel
	Special Education	
	Not Applicable, to	o young for school/ High School graduate or GED
	Status Unknown	
Academic Activity Level: *	Full academic load	
	Reduced academic	c load
	Ounable to particip	rate in academics due to disease or condition
	Ounable to particip	ate regularly due to dialysis
	Not Applicable, to	o young for school/ High School graduate or GED
	Status Unknown	
Source of Payment:		
Primary: *		
Specify:		
Height Measurement Date:		
Height: *	ft. in.	cm ST=
Weight Measurement Date:		
Weight: *	lbs	kg ST=
BMI:	kg/m ²	
Previous Transplants:	V (V)	
Previous Transplant Organ	Previous Transplant Date	Previous Transplant Graft Fail Date
	red here. Please contact the UNet Help Desk to col	nfirm more than three previous transplants by calling 800-978-4334 or by
emailing unethelpdesk@unos.org.		
Viral Detection:		
HIV Serostatus:*	Positive	
	Negative	
	Not Done	
	UNK/Cannot Discl	lose
CMV Status*	Positive	
	Negative	
	Not Done	
	OUNK/Cannot Discl	inse
HRV Surface Antihody Totalsk		
HBV Surface Antibody Total∗	Positive	
	Negative	
	Not Done	
	OUNK/Cannot Discl	lose
Conveight @ 2022 LL=#	ad Natwork for Organ Charing All -:-	hts reserved. OPTN use only. 091423
CODVITUTE & ZUZO UTIL	ou inclivion for Organ Stidillia. All 1191	ιιω ιουσίνου. Οι τιν αθο UIIIγ. Uθ 1443

HBV Core Antibody: *	Positive
	Negative
	ONOT Done
	OUNK/Cannot Disclose
HBV Surface Antigen: *	Positive
TIDY Surface Artugett. 4	
	○ Negative
	ONOT DONE
	OUNK/Cannot Disclose
HCV Serostatus: ★	Positive
	Negative
	Not Done
	UNK/Cannot Disclose
EBV Serostatus: *	Positive
	Negative
	Not Done
	UNK/Cannot Disclose
Vaccination Status:	
Did the recipient receive Hepatitis B vaccines prior to	YES NO UNK
transplant?:*	OTES ONG CORK
Reason not vaccinated:	Immunity
	Medical precaution
	Time constraints
	Patient objection
	Product out of stock
	Other, specify
Specify:	
NAT Results:	
HIV NAT: *	Positive
	Onegative Onegative
	Not Done
	UNK/Cannot Disclose
UDVANAT :	
HBV NAT: ∗	Positive
	Negative
	Not Done
	UNK/Cannot Disclose
HCV NAT: ∗	Positive
	Negative
	Not Done
	UNK/Cannot Disclose
Total Bilirubin:*	mg/dl ST=
Serum Albumin: *	g/dl ST=
Serum Creatinine:*	mg/dl ST=
Clinical Information : TRANSPLANT PROC	PENIDE
Multiple Organ Recipient	FFAIL

Multiple Organ Recipient	
Were extra vessels used in the transplant procedure:	
Copyright © 2023 United Network for Organ Sharing. All rights reserved. OPTN use only. 091423	

Procedure Information: Intestine Venous Drainage:**	OPortal OSystemic
Native Viscera Venous Drainage: *	OPortal OSystemic
Procedure Type:	Whole Intestine
	Intestine Segment
	Whole Intestine with Pancreas (Technical Reasons)
	Intestine Segment with Pancreas (Technical Reasons)
O T	
Organ Type: *	Stomach Small Intestine
	□ Duodenum
	□ Large Intestine
Preservation Information:	C Large Intestine
Total Ischemic Time (include cold, warm and	hvo CT-
anastomotic time):*	hrs ST=
Risk Factors: Recent Septicemia: *	OYES ONO OUNK
Exhausted Vascular Access: *	YES NO UNK
Previous Abdominal Surgery: *	CYES ONO OUNK
Dilated/Non-Functional Bowel Segments: *	OYES ONO OUNK
Other:	
Organ Check-in Information:	
Intestine Check- Date: Time: Time: In Date and Time:	Military time Time Zone:
Clinical Information : POST TRANSPLANT Graft Status:*	Functioning Failed
If death is indicated for the recipient, and the death was a result o	
TPN Dependent:	CYES ONO
IV Dependent:	YES NO
Oral Feeding:	YES NO
Tube Feed:	YES NO
Date of Graft Failure:	
Primary Cause of Graft Failure:	RECURRENT TUMOR
	ACUTE REJECTION
	CHRONIC REJECTION
	TECHNICAL PROBLEMS
	CINFECTION
	CLYMPHOPROLIFERATIVE DISEASE
	GRAFT VERSUS HOST DISEASE
	OISCHEMIA/NEC LIKE SYNDROME OTHER SPECIFY
Spacific	O STILL OF EOLI I
Specify:	
Did patient have any acute rejection episodes between transplant and discharge: *	Yes, at least one episode treated with anti-rejection agent
	Yes, none treated with additional anti-rejection agent No
	<u>∵110</u>

Are any medications given currently for maintenance or anti-rejection: *					
Immunosuppressive Medications					
View Immunosuppressive Medications					
Definitions Of Immunosuppressive Medications					
For each of the immunosuppressive medications listed, select Ind (Induction), Maint (Main prescribed for the recipient during the initial transplant hospitalization period, and for what Induction (Ind) immunosuppression includes all medications given for a <u>short finite perior</u> Though the drugs may be continued after discharge for the first 30 days after transplant, it Induction agents are usually polyclonal, monoclonal, or IL-2 receptor antibodies (example:	reason. If a m <u>d</u> in the periop will not be use	edication was not perative period for ed long-term for in	given, leave th the purpose of nmunosuppress	e associated box(es) preventing acute resive maintenance.	blank. jection.
drugs might be used for another finite period for rejection therapy and would be recorded a medication indicated, write the <u>total number of days the drug was actually administered</u> in apart then the total number of days would be 2, even if the second dose was given after the	as anti-rejection the space prov	n therapy if used finded. For example	or this reason.	For each induction	
Maintenance (Maint) includes all immunosuppressive medications given before, during of prednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, or Rapamune). rejection episodes, or for induction.					
Anti-rejection (AR) immunosuppression includes all immunosuppressive medications give post-transplant period or during a specific follow-up period, usually up to 30 days after the Thymoglobulin). When switching maintenance drugs (example: from tacrolimus to cyclospothe drugs should not be listed under AR immunosuppression, but should be listed under maximum immunosuppressive medication other than those listed is being administered (e.g., ne Immunosuppressive Medication field, and enter the full name of the medication in the space.	diagnosis of ac rine; or from r hintenance imn w monoclonal	cute rejection (examycophenolate monunosuppression. antibodies), select	imple: methylpi fetil to azathion : Ind, Maint, or	rednisolone, or or or or ne or	ection,
The specific of the specific o	o providedi <u>20</u>				
Drug used for induction, acute rejection, or maintenance		_			
	Ind.	Days	ST	Maint	AR
Steroids (prednisone, methylprednisolone, Solumedrol, Medrol)					Ц
Drugs used for induction or acute rejection	Ind.	Days	ST	Maint	AR
Atgam		Days			
Campath (alemtuzumab)					
Cytoxan (cyclophosphamide)				() () ()	
Methotrexate (Folex PFS, Mexate-AQ, Rheumatrex)					
Rituxan (rituximab)					
Simulect (basiliximab)					
Thymoglobulin					
Drugs primarily used for maintenance	Ind.	Days	ST	Maint	AR
Cyclosporine, select from the following:	IIIu.	Days	31	Planic	AK
- Gengraf					
- Neoral					
- Sandimmune					
- Generic cyclosporine					
Imuran (azathioprine, AZA)					
Leflunomide (LFL)					
Mycophenolic acid, select from the following:					
- CellCept (MMF)					

Copyright © 2023 United Network for Organ Sharing. All rights reserved. OPTN use only. 091423

Generic MMF (generic CellCept) Myfortic (mycophenolic acid)

- Rapamune (sirolimus)

Generic Myfortic (generic mycophenolic acid)
 mTOR inhibitors, select from the following:

Other immunosuppressive medication, specify:					
Other immunosuppressive medication, specify:					
	Ind.	Days	ST	Maint	AR
Other drugs					
- Generic tacrolimus (generic Prograf)					
- Prograf (tacrolimus)					
- Envarsus XR (tacrolimus XR)					
- Astagraf XL (extended release tacrolimus)					
Tacrolimus, select from the following:					
Nulojix (belatacept)					
- Zortress (everolimus)					
- Generic sirolimus					

Copyright \circledcirc 2023 United Network for Organ Sharing. All rights reserved. Confidential - OPTN Use Only

UNOS Policies & Terms